RT Journal Article
SR Electronic
T1 Grey and white matter micro-structure is associated with polygenic risk for schizophrenia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.06.21251073
DO 10.1101/2021.02.06.21251073
A1 Stauffer, Eva-Maria
A1 Bethlehem, Richard A.I.
A1 Warrier, Varun
A1 Murray, Graham K.
A1 Romero-Garcia, Rafael
A1 Seidlitz, Jakob
A1 Bullmore, Edward T.
YR 2021
UL http://medrxiv.org/content/early/2021/07/27/2021.02.06.21251073.abstract
AB Background Recent discovery of approximately 270 common genetic variants associated with schizophrenia has enabled polygenic risk scores (PRS) to be measured in the population. We hypothesized that normal variation in PRS would be associated with magnetic resonance imaging (MRI) phenotypes of brain morphometry and tissue composition.Methods We used the largest extant genome-wide association dataset (N = 69,369 cases and N = 236,642 healthy controls) to measure PRS for schizophrenia in a large sample of adults from the UK Biobank (Nmax = 29,878) who had multiple micro- and macro-structural MRI metrics measured at each of 180 cortical areas, seven subcortical structures, and 15 major white matter tracts. Linear mixed effect models were used to investigate associations between PRS and brain structure at global and regional scales, controlled for multiple comparisons.Results Polygenic risk was significantly associated with reduced neurite density index (NDI) at global brain scale, at 149 cortical regions, five subcortical structures and 14 white matter tracts. Other micro-structural parameters, e.g., fractional anisotropy, that were correlated with NDI were also significantly associated with PRS. Genetic effects on multiple MRI phenotypes were co-located in temporal, cingulate and prefrontal cortical areas, insula, and hippocampus. Post-hoc bidirectional Mendelian randomization analyses provided preliminary evidence in support of a causal relationship between (reduced) thalamic NDI and (increased) risk of schizophrenia.Conclusions Risk-related reduction in NDI is plausibly indicative of reduced density of myelinated axons and dendritic arborization in large-scale cortico-subcortical networks. Cortical, subcortical and white matter micro-structure may be linked to the genetic mechanisms of schizophrenia.Competing Interest StatementE.T.B. serves on the Scientific Advisory Board of Sosei Heptares and as a consultant for GlaxoSmithKline. All other authors declare no conflicts of interest.Funding StatementE.-M.S. is supported by a PhD studentship awarded by the Friends of Peterhouse. This research was co-funded by the National Institute of Health Research (NIHR) Cambridge Biomedical Research Centre and a Marmaduke Sheild grant to R.A.I.B. and V.W. E.T.B is an NIHR Senior Investigator. R.R.G. was funded by a Guarantors of Brain Fellowship. R.A.I.B. is supported by a British Academy Post-Doctoral fellowship and the Autism Research Trust. We wish to thank Dr Petra Vertes and Dr Lisa Ronan for their advice on research design and Dr Simon R White for his statistical advice and support. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We received ethical approval to access and analyse de-identified genetic and phenotypic data from the UK Biobank cohort from the University of Cambridge Human Biology Research Ethics Committee. Data usage was approved by the UK Biobank under the application number UK Biobank 20904. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe present project used imaging and genetic data made available through the UK Biobank database. Derived data will be made available through the UK Biobank access management system. Any code used to generate derived data is shared on GitHub. GWAS summary statistics for schizophrenia can be accessed from the Psychiatric Genomics Consortium . https://www.med.unc.edu/pgc/ https://github.com/ucam-department-of-psychiatry/UKB